Detection of MET exon 14 skipping mutations in non-small cell lung cancer: overview and community perspective

References

• Frampton GM, Ali SM, Rosenzweig M, et al., Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015;5(8):850–859.
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299–311.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. About lung cancer [ cited 2020 23 July]. Available from: https://www.cancer.org/cancer/lung-cancer/about.html
   Google Scholar
• Tong JH, Yeung SF, Chan AW, et al. MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis. Clin Cancer Res. 2016;22(12):3048–3056.
   PubMed Web of Science ®Google Scholar
• Yeung SF, Tong JHM, Law PPW, et al. Profiling of oncogenic driver events in lung adenocarcinoma revealed MET mutation as independent prognostic factor. J Thorac Oncol. 2015;10(9):1292–1300.
   PubMed Web of Science ®Google Scholar
• Vuong HG, Ho ATN, Altibi AMA, et al. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer – a systematic review and meta-analysis. Lung Cancer. 2018;123:76–82.
   PubMed Web of Science ®Google Scholar
• Awad MM, Oxnard GR, Jackman DM, et al. MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression. J Clin Oncol. 2016;34(7):721–730.
   PubMed Web of Science ®Google Scholar
• Schrock AB, Frampton GM, Suh J, et al. Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations. J Thorac Oncol. 2016;11(9):1493–1502.
   PubMed Web of Science ®Google Scholar
• Drilon A, Cappuzzo F, Ou SH, et al. Targeting MET in lung cancer: will expectations finally be MET? J Thorac Oncol. 2016;12(1):15–26.
   PubMed Web of Science ®Google Scholar
• Awad M, Lee J, Madison R, et al. Characterization of 1,387 NSCLCs with MET exon 14 (METex14) skipping alterations (SA) and potential acquired resistance (AR) mechanisms. Paper presented at: Annual Meeting of the American Society of Clinical Oncology; 2020 May 29–Jun 29–Jun 2; Virtual.
   Google Scholar
• Liu X, Chen X, Rong Y, et al. MET exon 14 skipping mutation, amplification and overexpression in pulmonary sarcomatoid carcinoma: a multi-center study. Transl Oncol. 2020;13(12):100868.
   PubMed Web of Science ®Google Scholar
• Saffroy R, Fallet V, Girard N, et al. MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung. Oncotarget. 2017;8(26):42428–42437.
   PubMedGoogle Scholar
• Awad MM, Leonardi GC, Kravets S, et al. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. Lung Cancer. 2019;133:96–102.
   PubMed Web of Science ®Google Scholar
• Wolf J, Balk C, Heist RS, et al. Natural history, treatment (Tx) patterns, and outcomes in MET dysregulated non-small cell lung cancer (NSCLC) patients (Pts). Poster presented at: 30th EORTC-NCI-AACR Symposium; 2018 November 13–16; Dublin, Ireland.
   Google Scholar
• Sabari JK, Leonardi GC, Shu CA, et al. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Ann Oncol. 2018;29(10):2085–2091.
   PubMed Web of Science ®Google Scholar
• Tabrecta [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2020.
   Google Scholar
• Wolf J, Seto T, Han JY, et al. Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med. 2020;383(10):944–957.
   PubMed Web of Science ®Google Scholar
• Tepmetko [prescribing information]. EMD Serono, Inc.; 2021.
   Google Scholar
• Paik PK, Felip E, Veillon R, et al. Tepotinib in non–small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med. 2020;383(10):931–943.
   PubMed Web of Science ®Google Scholar
• Drilon A, Clark JW, Weiss J, et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat Med. 2020;26(1):47–51.
   PubMed Web of Science ®Google Scholar
• Wolf J, Seto T, Han J-Y, et al. Capmatinib in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): efficacy data from the phase II GEOMETRY mono-1 study. Paper presented at: Annual Meeting of the American Society of Clinical Oncology; 2019 May 31–June 4; Chicago, IL.
   Google Scholar
• Paik PK, Sakai H, Felip E, et al. Tepotinib in patients with MET exon 14 (METex14) skipping advanced NSCLC: updated efficacy results from VISION Cohort A. Oral presented at: 2020 World Conference on Lung Cancer Singapore; 2021 January 28–31. p. MA11.05.
   Google Scholar
• Overbeck TR, Cron DA, Schmitz K, et al. Top-level MET gene copy number gain defines a subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosis. Transl Lung Cancer Res. 2020;9(3):603–616.
   PubMed Web of Science ®Google Scholar
• Mignard X, Ruppert A, Antoine M, et al. c-MET overexpression as a poor predictor of MET amplifications or exon 14 mutations in lung sarcomatoid carcinomas. J Thorac Oncol. 2020;13(12):1962–1967.
   Web of Science ®Google Scholar
• El-Deiry WS, Goldberg RM, Lenz H-J, et al. The current state of molecular testing in the treatment of patients with solid tumors, 2019. CA Cancer J Clin. 2019;69(4):305–343.
   PubMed Web of Science ®Google Scholar
• Freedman AN, Klabunde CN, Wiant K, et al. Use of next-generation sequencing tests to guide cancer treatment: results from a nationally representative survey of oncologists in the United States. JCO Precis Oncol. 2018;2:1–13.
   PubMed Web of Science ®Google Scholar
• Poirot B, Doucet L, Benhenda S, et al., MET exon 14 alterations and new resistance mutations to tyrosine kinase inhibitors: risk of inadequate detection with current amplicon-based NGS panels. J Thorac Oncol. 2017;12(10):1582–1587.
   PubMed Web of Science ®Google Scholar
• Smyth EC, Sclafani F, Cunningham D. Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors. Onco Targets Ther. 2014;7:1001–1014.
   PubMed Web of Science ®Google Scholar
• Van Der Steen N, Giovannetti E, Pauwels P, et al. cMET exon 14 skipping: from the structure to the clinic. J Thorac Oncol. 2016;11(9):1423–1432.
   PubMed Web of Science ®Google Scholar
• Sadiq AA, Salgia R. MET as a possible target for non-small-cell lung cancer. J Clin Oncol. 2013;31(8):1089–1096.
   PubMed Web of Science ®Google Scholar
• Baldacci S, Figeac M, Antoine M, et al. High MET overexpression does not predict the presence of MET exon 14 splice mutations in NSCLC: results from the IFCT PREDICT.amm study. J Thorac Oncol. 2020;15(1):120–124.
   PubMed Web of Science ®Google Scholar
• Ma PC, Jagadeeswaran R, Jagadeesh S, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 2005 Feb 15;65(4):1479–1488.
   PubMed Web of Science ®Google Scholar
• Kong-Beltran M, Seshagiri S, Zha J, et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res. 2006 Jan 1;66(1):283–289.
   PubMed Web of Science ®Google Scholar
• Cortot AB, Kherrouche Z, Descarpentries C, et al. Exon 14 deleted MET receptor as a new biomarker and target in cancers. J Natl Cancer Inst. 2017;109(5):djw262.
   Google Scholar
• Recondo G, Che J, Jänne PA, et al. Targeting MET dysregulation in cancer. Cancer Discov. 2020;10(7):922–934.
   PubMed Web of Science ®Google Scholar
• Drilon A. MET exon 14 alterations in lung cancer: exon skipping extends half-life. Clin Cancer Res. 2016;22(12):2832–2834.
   PubMed Web of Science ®Google Scholar
• Reungwetwattana T, Liang Y, Zhu V, et al. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: the why, the how, the who, the unknown, and the inevitable. Lung Cancer. 2017;103:27–37.
   PubMed Web of Science ®Google Scholar
• Noonan SA, Berry L, Lu X, et al. Identifying the appropriate FISH criteria for defining MET copy number-driven lung adenocarcinoma through oncogene overlap analysis. J Thorac Oncol. 2016;11(8):1293–1304.
   PubMed Web of Science ®Google Scholar
• Heist RS, Garon EB, Tan DSW, et al. Accurate detection of METex14 mutations in non-small-cell lung cancer (NSCLC) with comprehensive genomic sequencing: results from the GEOMETRY mono-1 study. Poster presented at: Sixth AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic; 2020 January 11–14; San Diego, CA.
   Google Scholar
• Le X, Kowalski D, Cho BC, et al. Liquid biopsy to detect MET exon 14 skipping (METex14) and MET amplification in patients with advanced NSCLC: biomarker analysis from VISION study. Cancer Res. 2020;80(16 suppl):Abstract 3385.
   Web of Science ®Google Scholar
• Schildhaus H-U, Schultheis AM, Ruschoff J, et al. MET amplification status in therapy-naive adeno- and squamous cell carcinomas of the lung. Clin Cancer Res. 2015;21(4):907–915.
   PubMed Web of Science ®Google Scholar
• Guo R, Berry LD, Aisner DL, et al. MET IHC is a poor screen for MET amplification or MET exon 14 mutations in lung adenocarcinomas: data from a tri-institutional cohort of the Lung Cancer Mutation Consortium. J Thorac Oncol. 2019;14(9):1666–1671.
   PubMed Web of Science ®Google Scholar
• Wolf J, Neal J, Mansfield A, et al. Comparison of clinical outcomes of patients with METΔex14 NSCLC treated with first-line capmatinib in the GEOMETRY mono-1 study with those of a cohort of real-world patients. Poster presented at: European Society for Medical Oncology Virtual Meeting; 2020 September 19–21.
   Google Scholar
• Lu S, Fang J, Li X, et al. Phase II study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14+). J Clin Oncol. 2020;38(suppl):Abstract 9519.
   Google Scholar
• Davies KD, Lomboy A, Lawrence CA, et al., DNA-based versus RNA-based detection of MET exon 14 skipping events in lung cancer. J Thorac Oncol. 2019;14(4):737–741.
   PubMed Web of Science ®Google Scholar
• Jurkiewicz M, Saqi A, Mansukhani MM, et al. Efficacy of DNA versus RNA NGS-based methods in MET exon 14 skipping mutation detection. J Clin Oncol. 2020;38(15 suppl):9036.
   Web of Science ®Google Scholar
• Jennings LJ, Arcila ME, Corless C, et al. Guidelines for validation of next-generation sequencing-based oncology panels: a joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists. J Mol Diagn. 2017;19(3):341–365.
   PubMed Web of Science ®Google Scholar
• Loyaux R, Blons H, Garinet P, et al. MET exon 14 screening strategy: how not to miss large deletions. Ann Oncol. 2020;31(suppl 5):S1218.
   Google Scholar
• Descarpentries C, Leprêtre F, Escande F, et al. Optimization of routine testing for MET exon 14 splice site mutations in NSCLC patients. J Thorac Oncol. 2018;13(12):1873–1883.
   PubMed Web of Science ®Google Scholar
• Solomon JP, Benayed R, Hechtman JF, et al. Identifying patients with NTRK fusion cancer. Ann Oncol. 2019;30(suppl 8):viii16–viii22.
   Google Scholar
• Ruan X, Sun Y, Wang W, et al. Multiplexed molecular profiling of lung cancer with malignant pleural effusion using next generation sequencing in Chinese patients. Oncol Lett. 2020;19(5):3495–3505.
   PubMed Web of Science ®Google Scholar
• Reeser J, Martin D, Miya J, et al. Validation of a targeted RNA sequencing assay for kinase fusion detection in solid tumors. J Mol Diagn. 2017;19(5):682–696.
   PubMed Web of Science ®Google Scholar
• Williams HL, Walsh K, Diamond A, et al. Validation of the Oncomine™ focus panel for next-generation sequencing of clinical tumour samples. Virchows Arch. 2018;473(4):489–503.
   PubMed Web of Science ®Google Scholar
• Wen S, Dai L, Wang L, et al. Genomic signature of driver genes identified by target next-generation sequencing in Chinese non-small cell lung cancer. Oncologist. 2019;24(11):e1070–e1081.
   PubMed Web of Science ®Google Scholar
• Cao J, Chen L, Li H, et al. An accurate and comprehensive clinical sequencing assay for cancer targeted and immunotherapies. Oncologist. 2019;24(12):e1294–e1302.
   PubMed Web of Science ®Google Scholar
• Kim EK, Kim KA, Lee CY, et al. Molecular diagnostic assays and clinicopathologic implications of MET exon 14 skipping mutation in non-small-cell lung cancer. Clin Lung Cancer. 2019;20(1):e123–e132.
   PubMed Web of Science ®Google Scholar
• Benayed R, Offin M, Mullaney K, et al. High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden. Clin Cancer Res. 2019;25(15):4712–4722.
   PubMed Web of Science ®Google Scholar
• Gutierrez ME, Choi K, Lanman RB, et al. Genomic profiling of advanced non-small cell lung cancer in community settings: gaps and opportunities. Clin Lung Cancer. 2017;18(6):651–659.
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Wood DE, Akerley W, et al. Non-small cell lung cancer, version 6.2015. J Natl Compr Canc Netw. 2015;13(5):515–524.
   PubMed Web of Science ®Google Scholar
• Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013;8(7):823–859.
   PubMed Web of Science ®Google Scholar
• Griesinger F, Eberhardt WE, Nusch A, et al. Biomarker testing in non-small cell lung cancer in routine care: analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315). Lung Cancer. 2021;152:174–184.
   PubMed Web of Science ®Google Scholar
• Singal G, Miller PG, Agarwala V, et al. Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database. JAMA. 2019;321(14):1391–1399.
   PubMed Web of Science ®Google Scholar
• Pennell NA, Arcila ME, Gandara DR, et al. Biomarker testing for patients with advanced non-small cell lung cancer: real-world issues and tough choices. Am Soc Clin Oncol Educ Book. 2019;39(39):531–542.
   PubMedGoogle Scholar
• Miller FA, Krueger P, Christensen RJ, et al. Postal survey of physicians and laboratories: practices and perceptions of molecular oncology testing. BMC Health Serv Res. 2009;9(1):131.
   PubMedGoogle Scholar
• Blazer KR, Nehoray B, Solomon I, et al. Next-generation testing for cancer risk: perceptions, experiences, and needs among early adopters in community healthcare settings. Genet Test Mol Biomarkers. 2015;19(12):657–665.
   PubMed Web of Science ®Google Scholar
• Gray SW, Hicks-Courant K, Cronin A, et al. Physicians’ attitudes about multiplex tumor genomic testing. J Clin Oncol. 2014;32(13):1317–1323.
   PubMed Web of Science ®Google Scholar
• De Moor JS, Gray SW, Mitchell SA, et al. Oncologist confidence in genomic testing and implications for using multimarker tumor panel tests in practice. JCO Precis Oncol. 2020;4:620–631.
   Web of Science ®Google Scholar
• Singh BP, Britton SL, Prins P, et al. Molecular profiling for malignancies: knowledge gaps and variable practice patterns among United States oncologists. Annual Meeting of the American Society of Clinical Oncology; 2019 May 31–June 4; Chicago, IL.
   Google Scholar
• Smeltzer MP, Wynes MW, Lantuejoul S, et al., The International Association for the Study of Lung Cancer global survey on molecular testing in lung cancer. J Thorac Oncol. 2020;15(9):1434–1448.
   PubMed Web of Science ®Google Scholar
• Menezes J, Joy V, Vora A What can we learn from oncologists? A survey of molecular testing patterns. Poster presented at: Association for Molecular Pathology Annual Meeting; 2018 November 1–3; San Antonio, TX.
   Google Scholar
• National Comprehensive Cancer Network. Non-small cell lung cancer (version 2.2021) [ cited 2021 January 20]. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx#nscl
   Google Scholar
• Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Mol Diagn. 2018;20(2):129–159.
   PubMed Web of Science ®Google Scholar
• Yu TM, Morrison C, Gold EJ, et al. Multiple biomarker testing tissue consumption and completion rates with single-gene tests and investigational use of Oncomine Dx target test for advanced non-small-cell lung cancer: a single-center analysis. Clin Lung Cancer. 2019;20(1):20–29.e8.
   PubMed Web of Science ®Google Scholar
• Pennell NA, Mutebi A, Zhou Z-Y, et al. Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non–small-cell lung cancer using a decision analytic model. JCO Precis Oncol. 2019;3:1–9.
   PubMed Web of Science ®Google Scholar
• Drilon A, Wang L, Arcila ME, et al. Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches. Clin Cancer Res. 2015;21(16):3631–3639.
   PubMed Web of Science ®Google Scholar
• Asad Zadeh Vosta Kolaei F, Cai B, Kanakamedala H, et al. Biomarker testing patterns and treatment outcomes in patients with advanced non-small cell lung cancer and MET exon 14 skipping mutations. Poster presented at: IASLC North America Conference on Lung Cancer; 2020 October 16–17; Virtual.
   Google Scholar
• Paik PK, Veillon R, Cortot AB, et al. Phase II study of tepotinib in NSCLC patients with METex14 mutations. J Clin Oncol. 2019;37(15 suppl):9005.
   Google Scholar
• Tan D, Lee D, Soo R, et al. Phase Ib results from a study of capmatinib (INC280) + EGF816 in patients with EGFR-mutant non-small cell lung cancer (NSCLC). IASLC World Conference on Lung Cancer; 2016 December 4–7; Vienna, Austria.
   Google Scholar
• Fujino T, Kobayashi Y, Suda K, et al. Sensitivity and resistance of MET exon 14 mutations in lung cancer to eight MET tyrosine kinase inhibitors in vitro. J Thorac Oncol. 2019;14(10):1753–1765.
   PubMed Web of Science ®Google Scholar
• Jamme P, Fernandes M, Copin MC, et al. Alterations in the PI3K pathway drive resistance to MET inhibitors in NSCLC harboring MET exon 14 skipping mutations. J Thorac Oncol. 2020;15(5):741–751.
   PubMed Web of Science ®Google Scholar
• Wu YL, Tsuboi M, John T, et al. Osimertinib in resected EGFR-mutated non-small cell lung cancer. N Engl J Med. 2020;383(18):1711–1723.
   PubMed Web of Science ®Google Scholar
• Recondo G, Guo R, Cravero P, et al. Clinical characteristics, genomic features, and recurrence risk of early-stage MET exon 14 mutant non-small cell lung cancer (NSCLC). Poster presented at: American Society of Clinical Oncology; 2020 May 29–Jun 2; Virtual.
   Google Scholar
• Chen AP, Eljanne M, Harris L, et al. National Cancer Institute basket/umbrella clinical trials: MATCH, LungMAP, and beyond. Cancer J. 2019;25(4):272–281.
   PubMed Web of Science ®Google Scholar
• Gerber DE, Oxnard GR, Mandrekar SJ, et al. ALCHEMIST: a clinical trial platform to bring genomic discovery and molecularly targeted therapies to early-stage lung cancer. J Clin Oncol. 2015;33(suppl): abstr TPS7583. 2015.
   PubMedGoogle Scholar